|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
Robert H. Morgan, Ed.D., slipped on his green and white court jester’s hat and began to sing a verse from Mariah Carey’s Hero, swaying his arms and moving about the room as if he were a glider. His one-minute song-and-dance act, performed at the University of Miami’s Excellence in Teaching Award ceremony, elicited smiles and quite a few chuckles from the audience. His musical merrymaking, however, wasn’t intended to amuse but to inform.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Hundreds of healthcare professionals, and Miller School students, faculty and staff filled the lobby, spa and group fitness areas of the Medical Wellness Center on April 29 for the first-ever Integrative Medicine Symposium and Expo.
Presentations, panel discussions and interactive demonstrations at the daylong forum provided a comprehensive look at the ever growing, but sometimes underrecognized field of complementary medicine.
The event has a been “a long time coming,” said chair Janet Konefal, Ph.D., M.P.H., L.Ac., who designed the symposium to foster the integration of conventional and complementary medicine among medical health professionals.
|
Stem cell researchers at the University of Miami Miller School of Medicine continue to blaze scientific trails with another first. They have received approval from the Food and Drug Administration for a study using a Helical Infusion catheter system to inject stem cells into the heart. BioCardia, a California-based biotechnology company, developed the minimally invasive percutaneous catheter system for the safe delivery of cells to the heart through a helical, or spiral-shaped needle. Joshua M. Hare, M.D., F.A.C.C., chief of the Cardiovascular Division and director of the Interdisciplinary Stem Cell Institute, will lead the research that is the world’s first stem cell trial that will compare two cell populations, bone marrow cells and mesenchymal cells, against placebo.
Mesenchymal cells are rare cells in bone marrow that can be grown in large numbers in a laboratory. For this study, they’ll be grown into stem cells and then injected back into the patient’s heart, using the BioCardia catheter. “We inject cells now in surgery,” explains Dr. Hare, “but this will be a non-surgical procedure using a catheter.”
Hospital is only Florida site where the alternative to open-heart surgery clinical trial is available
|
A few days after a revolutionary minimally invasive heart procedure was performed at University of Miami Hospital, the two patients were up-and-about and getting back to their regular activities. The procedure, a percutaneous valve replacement performed using catheters, is a new option for some older people who suffer from aortic stenosis but would not normally be treatable because they would be unable to withstand open-heart surgery and a long recovery period.
The disease, a narrowing of the valve that restricts blood flow, is a function of aging and has a high mortality rate if not treatable.
The new procedure, an FDA-approved clinical trial that is available at a handful of select facilities across the nation and only at UM in Florida, launches a “new era in the management of heart disease,” said William O’Neill, M.D., the Miller School’s executive dean for clinical affairs, who, along with Alan Heldman, M.D., clinical chief of the Cardiovascular Division, implanted the new heart valves.
To view press conference click here
|
The public roll-out of South Florida’s only university health system began with a spectacular event in the Schoninger Research Quadrangle on April 15. Not only was UHealth unveiled before a special gathering of Miller School supporters, but the newly created Society of Health Champions Annual Fund for the University of Miami Hospital was announced at the same time.
University of Miami Health System, a comprehensive network of university-based medical entities that together represent an innovative brand of the best health care, became finalized in December when the University purchased the former Cedars Medical Center and renamed it University of Miami Hospital.
|
In the continuation of a cutting-edge series of clinical trials researching the use of stem cells to treat heart disease, Miller School of Medicine physicians and scientists announced on Wednesday that for the first time a patient underwent a procedure that could hold the key to repairing damaged heart tissue, a potential life-saver for the millions of people suffering from heart failure.
The study's leader, Joshua M. Hare, M.D., F.A.C.C., the Miller School's chief of the Cardiovascular Division and director of the Interdisciplinary Stem Cell Institute, said following the patient’s triple bypass surgery Monday, mesenchymal stem cells, or a placebo, were injected directly in the patient’s heart.
To view press conference click here
Thomas R. Insel, M.D., director of the National Institute of Mental Health, received the 2008 Margaret Ann Aitcheson Humanitarian Award for his visionary commitment to advancing mental health research during a ceremony on April 16 at the University of Miami Miller School of Medicine.
The Miller School’s burgeoning reputation in human genomics rose a few more notches Monday, buoyed by the same philanthropic ally that helped usher the school into the realm of genetics research eight years ago.
Glacial melting, rising sea levels, heavier rainfalls and more intense heat waves are all unequivocal signs of climate change that point to a planet in peril.
Information on |
|
Copyright © 1997-2007 University of Miami, All Rights Reserved. |
Terms of Use Privacy Statement Contact Us |
Medical Disclaimer Site Map Web Technology |